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Collagen crosslinksEldecalcitol (ELD), an active form of vitamin D analog approved for the treatment of osteoporosis in Japan, in-
creases lumbar spine bone mineral density (BMD), suppresses bone turnover markers, and reduces fracture
risk in patients with osteoporosis. We have previously reported that treatment with ELD for 6 months improved
the mechanical properties of the lumbar spine in ovariectomized (OVX) cynomolgus monkeys. ELD treatment
increased lumbar BMD, suppressed bone turnover markers, and reduced histomorphometric parameters of
both bone formation and resorption in vertebral trabecular bone. In this study, we elucidated the effects of ELD
on bone quality (namely, mineralization, microarchitecture, microdamage, and bone collagen crosslinks) in
OVX cynomolgus monkeys in comparison with OVX-vehicle control monkeys. Density fractionation of bone
powder prepared from lumbar vertebrae revealed that ELD treatment shifted the distribution proﬁle of bone
mineralization to a higher density, and backscattered electronmicroscopic imaging showed improved trabecular
bone connectivity in the ELD-treated groups. Higher doses of ELD more signiﬁcantly reduced the amount of
microdamage compared to OVX-vehicle controls. The fractionated bone powder sampleswere divided according
to their density, and analyzed for collagen crosslinks. Enzymatic crosslinks were higher in both the high-density
(≥2.0 mg/mL) and low-density (b2.0 mg/mL) fractions from the ELD-treated groups than in the corresponding
fractions in the OVX-vehicle control groups. On the other hand, non-enzymatic crosslinkswere lower in both the
high- and low-density fractions. These observations indicated that ELD treatment stimulated the enzymatic reac-
tion of collagen crosslinks and bonemineralization, but prevented non-enzymatic reaction of collagen crosslinks
and accumulation of bone microdamage. Bone anti-resorptive agents such as bisphosphonates slow down bone
remodeling so that bonemineralization, bone microdamage, and non-enzymatic collagen crosslinks all increase.
Bone anabolic agents such as parathyroid hormone decrease bone mineralization and bone microdamage by
stimulating bone remodeling. ELD did not ﬁt into either category. Histological analysis indicated that the ELD
treatment strongly suppressed bone resorption by reducing the number of osteoclasts, while also stimulating
focal bone formation without prior bone resorption (bone minimodeling). These bidirectional activities of ELD
may account for its unique effects on bone quality.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
Bone mineral density (BMD) and bone quality are two major com-
ponents of bone strength. Bone quality consists of bone geometry,
bone microarchitecture, bone microdamage, bone mineralization, and
bone material properties. These determinants of bone quality are regu-
lated by bone turnover and the degree of oxidative stress [1–3].. This is an open access article underEldecalcitol [1α,25-dihydroxy-2β-(3-hydroxypropyloxy) vitamin D3;
ELD], an analog of calcitriol [1α,25-dihydroxyvitamin D3; 1,25(OH)
2D3], has been demonstrated to increase bone mass, to suppress bone
turnover markers, and to enhance bone strength in rodents [4,5] and
in non-human primates [6]. ELD suppresses RANKL expression in oste-
oblasts [7], suppresses differentiation of preosteoclasts tomature osteo-
clasts [8], stimulates cell-migration of osteoclast precursor monocytes
[9], and therefore, reduces the number of mature osteoclasts on the
bone surface. A 3-year randomized, double-blind, active-comparator,
clinical trial of ELD in postmenopausal women with osteoporosisthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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bral fractures and wrist fractures, increased both lumbar spine and hip
BMD, and suppressed bone turnover markers in comparison to
alfacalcidol (1α-hydroxyvitamin D3) [10]. Deterioration of bone archi-
tecture in the hip was reduced by ELD treatment [11]. A post-hoc anal-
ysis revealed that, compared with placebo, ELD reduced incidence of
vertebral fractures by approximately 50% in osteoporotic patients with
prevalent fractures [12]. This series of results raises an important ques-
tion. Treatment with ELD increases lumbar spine BMD by only 3% per
year and reduces bone turnover markers by approximately 30% per
year compared with the pretreatment level. On the other hand, treat-
ment with most bisphosphonates increases lumbar spine BMD by
more than 5% per year and reduces bone turnover markers by 50%–
60% per year. Despite itsmore restrained effects on BMD and bone turn-
over markers, the anti-fracture activity of ELD is comparable to that of
bisphosphonates [13]. These differences suggest that in addition to the
effects of ELD on BMD and bone turnover markers, the anti-fracture ac-
tivity of ELD treatment may be attributable to improved bone quality.
We have previously shown that treatment with 0.1 μg/kg/day and
0.3 μg/kg/day of ELD increases lumbar spine and hip BMD, suppresses
bone turnover markers, and eventually increases bone mechanical
properties of lumbar vertebrae in ovariectomized (OVX) cynomolgus
monkeys [6]. Unlike rodent models, ovariectomized non-human pri-
mates have a skeletal anatomy and bone material properties in terms
of collagen crosslink formation similar to those of postmenopausal
women, with intracortical bone remodeling and increased bone turn-
over and bone loss associated with estrogen deﬁciency [14,15].
Regarding bonematerial properties, collagen crosslinking is an inde-
pendent determinant of bone strength [3,16]. Bone collagen crosslinks
can be divided into immature and mature enzymatic crosslinks and
glycation- or oxidation-induced non-enzymatic senescent crosslinks
(advanced glycation end products, AGEs). Enzymatic crosslink forma-
tion has positive effects on the mechanical properties of bone, confer-
ring ﬂexibility without brittleness [17–21]. In contrast, AGE crosslinks
result in brittle collagen ﬁbers, thereby leading to microdamage and
bone fragility [17,22,23]. AGE crosslinks are formed by oxidation or
glycation reactions in a time-dependent manner, and are regulated by
tissue turnover rate [22,24], the degree of oxidative stress [25,26], or
glycation level [17,23]. Pentosidine is a well-established intermolecular
crosslinking AGE and is used as a surrogate marker of total AGE forma-
tion [17,26–30].
In this study, in order to evaluate the effect of ELD on bone material
and structural properties, we analyzed bone mineralization, bone
microarchitecture, bonemicrodamage, immature andmature enzymat-
ic collagen crosslinks, and AGEs in the bone samples collected for the
OVX cynomolgus monkey study previously reported [6].
Materials and methods
Animals and experimental design
All animal procedures were as previously reported [6]. Brieﬂy, 40 fe-
male cynomolgusmonkeys, at least 9 years of age, were housed in pairs
and fed twice daily with food supplements and/or fresh fruit, and had
free access to water. The animal room environment was controlled,
with settings targeted at a temperature of 22 ± 3 °C, humidity of
50 ± 20%, photoperiod of 12 h light and 12 h dark, and 12 air changes
per hour. Two separate experiments were conducted, one experiment
using a dose of 0.1 μg/kg ELD and a corresponding OVX-vehicle control
group and the other experiment using 0.3 μg/kg ELD and a correspond-
ing OVX-vehicle control group. Medium chain triglyceride was used for
the vehicle solution. For each experiment, 20 animals were randomly
assigned to either the OVX-vehicle control group or the ELD group
(n = 10/group). The groups were balanced to ensure that age, body
weights, whole body bone mineral content (BMC), and lumbar spine
BMD were equivalent across groups within each experiment.Daily treatment started the day following ovariectomy, with either
vehicle alone (OVX-Veh1 or OVX-Veh2) or ELD (at 0.1 μg/kg in the
ﬁrst experiment or 0.3 μg/kg in the second experiment), and continued
for 6 months. Animals were euthanized under anesthesia by exsangui-
nation, and bone samples were excised. The study was approved by
the Charles River Montreal Animal Care Committee and was performed
in a facility accredited by the Association for Assessment and Accredita-
tion of Laboratory Animal Care.
Density fractionation
Density fractionation was carried out as previously reported
[31–33]. Brieﬂy, the third lumbar vertebrae (L3) were crushed and
washed in 0.2 M Tris–HCl buffer (pH 7.4) to remove bone marrow, ly-
ophilized, and then defatted in 2:1 (v:v) chloroform:methanol solution.
The bone pieces were then pulverized in a percussionmill cooled in liq-
uid nitrogen (Spex Freezer Mill; Spex Sampleprep, Metuchen, NJ, USA)
and then sieved in a sonic sifter to separate bone particles less than
20 μm in size. The bone powder was then chemically “fractionated”
(into seven fractions from b 1.8 g/mL to N 2.1 g/mL) in a bromoform–
toluene mixture by a method of stepwise centrifugation [33]. Approxi-
mately 200 mg of the sieved bone was added to a polyallomer centri-
fuge tube containing 35 mL of a 1.95 g/mL density solution (calibrated
with sink ﬂoats) for cancellous bone. The tubes were sonicated to
achieve a homogeneous suspension of the powder, whichwas then cen-
trifuged at 10,000 rpm for 30 min in a Beckman L5-55 ultracentrifuge
using an SW20 rotor. The density of the supernatant was adjusted to
1.9 g/mL via the addition of toluene, and the modiﬁed solution was re-
centrifuged. In a similar way, each precipitate obtained from a solution
of progressively decreasing density (in 0.05 g/mL steps) was collected.
For the range ofmineral densities greater than 1.95 g/mL, the precipitates
obtained from an initial 2.0 g/mL density solution was re-suspended in a
solution of density 2.1 g/mL. Similarly, successive centrifugation of the
precipitate at progressively higher densities (0.05 g/mL steps) deter-
mined the higher density fractions.
Removal of organic solvent from the series of density fractions was
achieved by a “rinse” centrifugation in 100% ethyl alcohol. The samples
were then dried in a desiccator at room temperature. The contribution
of each fraction, relative to the original weight of unfractionated bone,
was calculated to determine a mineralization proﬁle for each group.
Bone microdamage assessment
The fourth lumbar vertebrae (L4) were processed for microdamage
assessment by bulk staining in basic fuchsin. Using 1% basic fuchsin dis-
solved in increasing concentrations of ethanol, specimens were stained
according to the following schedule: 4 h in 80%, 4 h in 80%, 4 h in 95%,
overnight in 95%, 4 h in 100%, and 4 h in 100%. At each step, the solution
was replacedwith fresh solution after 2 h. Boneswere placed under vac-
uum (20 in Hg) for all stages during the day and left on the bench top
overnight. Following staining, bones were washed twice in 100% etha-
nol (5 min each), and placed in 100% methylmethacrylate (MMA;
Sigma-Aldrich) under vacuum for 4 h. Specimenswere then transferred
to a solution of MMA+ 3% dibutyl phthalate (DBP; Sigma-Aldrich) for
3–7 days under vacuum and then embedded using MMA + DBP +
0.25% catalyst (Perkadox 163; Akzo Nobel Chemicals, Pasadena, USA).
Mid-sagittal sections 80–100 μm thick were cut using a diamond wire
saw (Histosaw; Delaware Diamond Knives, Inc., DE, USA).
Histological measurements were made using a microscope
interfaced with Bioquant analysis software (Bioquant OSTEO 7.20.10;
Bioquant Image Analysis Co., TN, USA). Measurements were carried
out on two sections per animal to increase the probability of ﬁnding
cracks. A region of interest approximately 5 × 5 mm, located 1 mm
below the cranial plateau, was used for sampling, and linear
microcracks were identiﬁed as previously described [34]. Measure-
ments included crack length (Cr.Le; 200× magniﬁcation) (μm) and
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density (Cr.Dn = Cr.N/bone area) (/mm2) and crack surface density
(Cr.S.Dn = Cr.N × Cr.Le / bone area) (μm/mm2).
Bone microarchitecture assessment by backscattered electron microscopy
The resin-embedded L4 vertebrae blocks prepared for microdamage
analysis were cut with a saw, polished to a 1 μm diamond ﬁnish, then
carbon coated. We used a scanning electron microscope (XL30;
Philips/FEI, Oregon, USA) ﬁtted with a backscattered electron detector
(Philips/FEI). The signal was calibrated using C (Z = 6) and A1 (Z =
13), then the settings were changed to increase the contrast of the
bone signal (Z = approx. 10). During the acquisition session, we
controlled the drift of the signal using SiO2 as a standard (only for slight
adjustments). The accelerating voltage was 20 kV. Digital images were
collected at 80× magniﬁcation; adjacent images were obtained on
each block.
Image analysis was performedwith a Quantimet 500 IWusing Qwin
Pro (Leica Microsystems, Cambridge, UK). The images were converted
to binary images using a constant threshold of 85. The binary images
were then skeletonized and pruned to quantify the number of nodes
(/mm2), number of termini (/mm2), and different types of struts [32].
We calculated the lengths of node-to-node struts (mm/mm2), node-
to-terminus struts (mm/mm2), and terminus-to-terminus struts
(mm/mm2), and the total strut length (mm/mm2). Of these parameters,
the increase in the number of nodes, node-to-node struts, and node-to-
terminus struts can be related to the connectedness of the structure.
Struts reaching the borders of the images were not considered except
for the total strut length.
Collagen crosslink analysis
The procedure to analyze collagen crosslinks in bone after the density
fractionation was as reported previously [27,29,30]. Brieﬂy, density-
fractionated bone powders of the third lumbar vertebrae were subject-
ed to the collagen crosslink analysis. Fractionated bone powders were
pooled into two fractions: low-density fraction (b2.0 mg/mL) and
high-density fraction (≥2.0 mg/mL). We deﬁned the boundary line
between the low- and high-density fractions at 2.0 mg/mL based on
the report by Sodek et al. [31]. By separating bone at the 2.0 mg/mL
boundary line, we obtained sufﬁcient bone from both low- and high-
density fractions for triplicate analyses of two different density frac-
tions, suitable for estimating the collagen maturation process [29,30].
Toluene and bromoform used for the bone density fractionation do
not affect the biochemical nature of bone collagen and its crosslinks
[30].
Each sample of bone powder was demineralized twice with 0.5 M
EDTA in 50 mM Tris buffer (pH 7.4) for 96 h at 4 °C. The demineralized
bone residues were then suspended in 0.15 M potassium phosphate
buffer (pH 7.6) and reduced at 37 °C with NaBH4. The reduced speci-
mens were hydrolyzed in 6 N HCl at 110 °C for 24 h. Hydrolysates
were analyzed for the content of crosslinks and hydroxyproline on a
Shimadzu LC9 HPLC ﬁtted with a cation exchange column (0.9 ×
10 cm, Aa pack-Na; JASCO, Ltd., Tokyo, Japan) linked to an inlineﬂuores-
cence ﬂow monitor (RF10AXL; Shimadzu, Shizuoka, Japan). It was
assumed that collagenweighed 7.5 times themeasured hydroxyproline
weight with a molecular weight of 300,000. The resulting data were
used to calculate the cross-link values asmol/mol of collagen. Reducible
immature divalent crosslinks (dehydrodihydroxylysinonorleucine,
deH-DHLNL; dehydrohydroxylysinonorleucine, deH-HLNL; and
dehydrolysinonorleucine, deH-LNL) were identiﬁed and quantiﬁed ac-
cording to their respective reduced forms (dihydroxylysinonorleucine,
DHLNL; hydroxylysinonorleucine, HLNL; and lysinonorleucine, LNL).
The mature crosslinks and common amino acids such as hydroxyproline
were detectable with post-column derivatization using o-
phthalaldehyde, whereas the mature trivalent pyridinium crosslinks(pyridinoline, Pyr; and deoxypyridinoline, Dpyr) and the non-enzymatic
crosslink pentosidine (Pen) were detected by natural ﬂuorescence.
The HPLC system we established enabled us to determine enzymatic
and non-enzymatic crosslink contents within a linear range of 0.2 to
600 pmol in bone specimens. The total content of AGEs as well as
pentosidine content was determined by the method of Tang et al. [35].
Brieﬂy, AGE content was determined by using a ﬂuorescence reader at
370 nm excitation and 440 nm emission (JASCO FP6200, JASCO) and
normalized to a quinine sulfate standard. Data were expressed as
mean ± standard deviation (SD).
Bone histology
Each animal had been injected intravenouslywith 8mg/kg of calcein
15 days and 5 days prior to termination. L2 vertebraewere collected for
bone histology. All bone sampleswere ﬁxed in 10% neutral-buffered for-
malin for 3 days and transferred to 70% ethanol. Bones were then
trimmed, dehydrated, and embedded in methyl methacrylate. Sagittal
histological sections of L2 vertebrae were observed under a light micro-
scope after toluidine blue staining for evaluating bone histology, or
under a ﬂuorescence microscope for visualizing calcein labeling
(Nikon Eclipse E800; Nikon, Tokyo, Japan).
Statistical analysis
Density fractionation
Data were analyzed as previously described [36]. The way to esti-
mate if two distributions differ is to calculate the logit function of each
distribution. For these experiments, the logit number of each sample
is: ln(proportion of ≥ 2.00 mg/mL fraction) − ln(proportion
of b 2.00 mg/mL fraction). The statistical analyses were performed
using SPSS software (IBM, Armonk, NY, USA).
Bone microdamage assessment
Data from each experiment was evaluated separately using the SAS
software package (SAS Institute, Inc., Cary, NC, USA). Group variance
was evaluated using the Shapiro–Wilks test. If the assumption of
normality was met (p ≥ 0.05), a parametric two-tailed t-test was per-
formed to determine differences between the control and treated
groups. If the assumption of normality was not met, for either/both
groups (p b 0.05), the non-parametric Wilcoxon–Mann–Whitney test
(two-tailed) was used to compare the control and treated groups.
Spearman's rank correlation coefﬁcient method was used to analyze
the correlation between the contents of Pen and total ﬂuorescent
AGEs in bone. For all comparisons, both parametric and non-
parametric tests are reported, with p b 0.05 considered statistically
signiﬁcant.
Bone microarchitecture assessment
The statistical analyses were performed using SPSS software (IBM,
Armonk, NY, USA). Independent Student's t-tests were done between
the ELD treatment group and corresponding vehicle control group for
each experiment. P-values less than 0.05 were considered signiﬁcant.
Collagen crosslink analysis
Analysis of variance was performed using the SAS software package
(SAS Institute). The signiﬁcance of differences (in comparison with the
OVX-vehicle control group) was determined using the Tukey–Kramer
test. P-values less than 0.05 were considered statistically signiﬁcant.
Results
Bone mineralization assessment by density fractionation
Treatment with 0.1 μg/kg or 0.3 μg/kg of ELD shifted the distribution
proﬁle of bone mineralization to a higher density compared with the
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Fig. 1. Distribution proﬁles of bonemineralization as assessed by density fractionation. (A) Experiment 1: ELD 0.1 μg/kg group (gray bars) versus OVX-vehicle control (OVX-Veh1; white
bars). (B) Experiment 2: ELD 0.3 μg/kg group (gray bars) versus OVX-vehicle control (OVX-Veh2; white bars). Data are presented as mean + SEM. Box-and-whisker plots showmedian,
25th and 75th quartiles, and complete data range of the logit numbers of Experiment 1 (C) and Experiment 2 (D).
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of the ELD 0.3 μg/kg group and the OVX-Veh2 control group were
−0.394 and 1.009, respectively (Fig. 1D). The shift in the value of the
logit function between two groupswas signiﬁcant (p=0.0002). The av-
erage logit number of the ELD 0.1 μg/kg group and the OVX-Veh1 were
1.439 and 1.842, respectively (Fig. 1C). But there was no signiﬁcant dif-
ference between the value of the logit function of the ELD 0.1 μg/kg
group and the OVX-Veh1 control group (p= 0.270).Table 2
Evaluation of trabecular connectivity in lumbar vertebrae.
Experiment 1 OVX-Veh1 ELD 0.1 μg/kg p-Value
Number of termini (/mm2) 2.55 ± 0.26 2.19 ± 0.19 0.253
Number of nodes (/mm2) 1.68 ± 0.15 2.23 ± 0.15 0.020
Terminus to terminus strut length
(mm/mm2)
0.24 ± 0.02 0.13 ± 0.02 0.003
Node to terminus strut length
(mm/mm2)
0.78 ± 0.06 0.76 ± 0.04 0.771Bone microdamage
There were no signiﬁcant differences between the ELD 0.1 μg/kg
group and OVX-Veh1 control group for any of the microdamage vari-
ables measured (Table 1). The ELD 0.3 μg/kg group had half as many
cracks as the OVX-vehicle group (p = 0.052). When normalized for
bone area, the ELD 0.3 μg/kg group had signiﬁcantly lower crack density
(p= 0.027) and crack surface density (p= 0.049) as compared to the
OVX-Veh2 control group. There was no signiﬁcant difference between
groups for crack length (Table 1).Table 1
Microdamage analysis of vertebral trabecular bone.
Crack
number
Crack
length
(μm)
Crack
density
(/mm2)
Crack surface
density
(μm/mm2)
OVX-Veh1 10.6 ± 3.3 78.0 ± 3.6 1.21 ± 0.23 97.7 ± 21.0
ELD 0.1 μg/kg 14.2 ± 4.1 77.7 ± 2.2 1.63 ± 0.51 132.5 ± 43.6
p= 0.496 p= 0.940 p= 0.464 p= 0.478
OVX-Veh2 20.8 ± 4.9 75.6 ± 3.2 2.06 ± 0.45 159.5 ± 36.2
ELD 0.3 μg/kg 10.1 ± 2.0 80.5 ± 3.8 0.92 ± 0.18 77.3 ± 17.1
p= 0.052 p= 0.353 p= 0.027 p= 0.049
Data are represented as mean ± SEM. p-Values less than 0.05 are considered statistically
signiﬁcant.Bone microarchitecture
The results of the strut analysis of the trabecular bone from the L4
vertebrae are shown in Table 2. These data were derived from the
backscattered electron microscopic images (Fig. 2). The results are con-
sistent with increased trabecular connectivity as demonstrated by a
higher number of nodes and node-to-node strut lengths as well as a
lower number of termini and terminus-to-terminus strut lengths with
both 0.1 μg/kg and 0.3 μg/kg of ELD.Node to node strut length (mm/mm2) 0.79 ± 0.10 1.12 ± 0.07 0.015
Total strut length (mm/mm2) 2.00 ± 0.10 2.25 ± 0.09 0.088
Anisotropy ratio 0.80 ± 0.02 0.81 ± 0.01 0.622
Experiment 2 OVX-Veh2 ELD 0.3 μg/kg p-Value
Number of termini (/mm2) 2.82 ± 0.12 1.89 ± 0.2 0.002
Number of nodes (/mm2) 1.97 ± 0.09 2.3 ± 0.13 0.079
Terminus to terminus strut length
(mm/mm2)
0.24 ± 0.02 0.12 ± 0.02 0.002
Node to terminus strut length
(mm/mm2)
0.84 ± 0.02 0.78 ± 0.07 0.388
Node to node strut length (mm/mm2) 0.82 ± 0.08 1.11 ± 0.08 0.025
Total strut length (mm/mm2) 2.09 ± 0.07 2.2 ± 0.08 0.364
Anisotropy ratio 0.79 ± 0.02 0.81 ± 0.02 0.614
Data are presented as mean ± SEM. p-Values less than 0.05 are considered statistically
signiﬁcant.
A: OVX-Veh1 B: ELD 0.1µg/kg C: OVX-Veh2 D: ELD 0.3µg/kg
Fig. 2. Backscattered electron microscopic imaging of the sagittal plane of lumbar vertebrae (L4). (A) OVX-vehicle control (OVX-Veh1), (B) ELD 0.1 μg/kg group, (C) OVX-vehicle control
(OVX-Veh2), (D) ELD 0.3 μg/kg group.
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The total enzymatic crosslink content (the sumof DHLNL, HLNL, LNL,
Pyr, andDpyr) in both low- andhigh-density fractions frombones of the
ELD-treated (0.1 and 0.3 μg/kg) groups was signiﬁcantly higher than
those of the corresponding OVX-vehicle control groups (Figs. 3A, C,
and Table 3). Notably, immature reduced forms of enzymatic crosslinks
(DHLNL, HLNL, and LNL) signiﬁcantly andmarkedly increased with ELD
treatment, whereas increases in mature non-reducible forms of enzy-
matic crosslinks (Pyr and Dpyr) by the ELD treatment were signiﬁcant
but moderate (Table 3).High-density fraction
Low-density fraction High-density fraction
OVX-Veh1 ELD 
To
ta
l e
nz
ym
at
ic 
cr
os
sli
nk
s 
m
o
l/m
ol
 o
f c
ol
la
ge
n
OVX-Veh1 ELD 
p=0.0004 p<0.0001
A B
ELD OVX-Veh2 ELD 
To
ta
l e
nz
ym
at
ic 
cr
os
sli
nk
s 
m
o
l/m
ol
 o
f c
ol
la
ge
n
OVX-Veh2
p<0.0001
C D
p<0.0001
Low-density fraction
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the ratio of total mature enzymatic crosslinks (Pyr + Dpyr) to total
immature crosslinks (DHLNL + HLNL + LNL) [29,30,35] (Table 3).
The maturation index showed a signiﬁcant reduction in both low-
and high-density fractions of bone from the ELD-treated groups
compared with those from the corresponding OVX-vehicle control
groups. Conversely, contents of Pen, the non-enzymatic AGE type
of crosslink, were signiﬁcantly lower in both low- and high-density
fractions from bones of the ELD-treated groups than in those of
the corresponding OVX-vehicle control groups (Figs. 3B, D, and
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p=0.0479
p=0.0013
p=0.0120
p=0.0047
ensity fraction (b2.0mg/mL) and high-density fraction (≥2.0mg/mL). (A) Total content of
ks in bone from theOVX-vehicle control (OVX-Veh1) and ELD 0.1 μg/kg group, (B) content
0.1 μg/kg group, (C) total content of enzymatic crosslinks: the sum of immature (DHLNL,
h2) and ELD 0.3 μg/kg group, (D) content of non-enzymatic crosslink (Pen) in bone from
edian, 25th and 75th quartiles, and complete data range.
Table 3
Comparison of enzymatic and non-enzymatic crosslink contents between the OVX-vehicle controls and the ELD-treated groups.
Enzymatic crosslinks Non-enzymatic crosslinks
Immature divalent forms
(mol/mol of collagen)
Mature trivalent forms
(mol/mol of collagen)
Collagen maturation index
(Pyr + Dpyr) /
(DHLNL + HLNL + LNL)
Total AGEs
(ng quinine/mg
of collagen)
Pentosidine
(mmol/mol
of collagen)
DHLNL HLNL LNL Pyr Dpyr
Low-density fraction
OVX-Veh1 0.522 ± 0.060 0.139 ± 0.031 2.131 ± 0.382 0.105 ± 0.007 0.018 ± 0.007 0.185 ± 0.015 129 ± 11.5 2.131 ± 0.382
ELD 0.1 μg/kg 0.636 ± 0.118⁎ 0.260 ± 0.053⁎ 1.753 ± 0.258⁎ 0.132 ± 0.012⁎ 0.035 ± 0.007⁎ 0.189 ± 0.027 118.8 ± 11.8 1.753 ± 0.258⁎
High-density fraction
OVX-Veh1 0.466 ± 0.056 0.153 ± 0.028 2.742 ± 0.570# 0.103 ± 0.013 0.023 ± 0.009 0.202 ± 0.025 151.3 ± 30.0# 2.742 ± 0.570#
ELD 0.1 μg/kg 0.620 ± 0.182⁎ 0.298 ± 0.078⁎ 2.097 ± 0.349⁎ 0.119 ± 0.007⁎,# 0.031 ± 0.005⁎ 0.172 ± 0.045 141.1 ± 12.9# 2.097 ± 0.349⁎,#
Low-density fraction
OVX-Veh2 0.413 ± 0.075 0.150 ± 0.070 2.537 ± 0.588 0.112 ± 0.018 0.026 ± 0.011 0.249 ± 0.045 132.3 ± 14.0 2.537 ± 0.588
ELD 0.3 μg/kg 0.738 ± 0.133⁎ 0.263 ± 0.063⁎ 1.855 ± 0.448⁎ 0.122 ± 0.016 0.044 ± 0.006⁎ 0.169 ± 0.035⁎ 110.0 ± 26.2⁎ 1.855 ± 0.448⁎
High-density fraction
OVX-Veh2 0.410 ± 0.088 0.143 ± 0.063 2.943 ± 0.749 0.119 ± 0.018 0.029 ± 0.013 0.275 ± 0.046 161.0 ± 27.6# 2.943 ± 0.749
ELD 0.3 μg/kg 0.734 ± 0.161⁎ 0.276 ± 0.077⁎ 2.166 ± 0.417⁎ 0.126 ± 0.016 0.037 ± 0.006# 0.165 ± 0.030⁎ 140.5 ± 25.0# 2.166 ± 0.417⁎
Abbreviations: dihydroxylysinonorleucine, DHLNL; hydroxylysinonorleucine, HLNL; lysinonorleucine, LNL; pyridinoline, Pyr; deoxypyridinoline, Dpyr; pentosidine, Pen.
Data are represented as mean ± SD.
⁎ : p b 0.05 versus OVX-vehicle control.
# : p b 0.05 between low-density fraction and high-density fraction in the same treatment groups.
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evident (Table 3). Pen is just a component of various AGEs, and because
the content of Pen in bone correlates positively with the total amount of
ﬂuorescent AGEs, the measurement of Pen can be used as a surrogate
marker of total AGE formation [37]. In this study, we also conﬁrmed
that there was a signiﬁcant and positive correlation between the con-
tent of Pen and the total ﬂuorescent AGEs in bone (R2 = 0.339, p b
0.0001) (data not shown). The contents of the senescent crosslinking
Pen and total contents of AGEs were signiﬁcantly higher in the high-
density fractions than in the low-density fractions in both the OVX-
vehicle and ELD-treated groups (all p b 0.05, Table 3).
Bone histology
Trabecular bone sections of the ELD-treated cynomolgus monkeys
demonstrated many “bud-like” bone formation patterns (Fig. 4A).
Convex, bud-like focal deposits of bone matrix were observed on theA
trabecula
trabecula
bone marrow
B
trabecula
bone marrow 
trabeculal
l
l
 
l
Fig. 4. Representative histological images of boneminimodeling. Trabecular bone sections of lumbar vertebrae frommonkeys treated with ELD 0.3 μg/kgwere observed under a light mi
croscope or ﬂuorescence microscope. (A) Histological section with toluidine blue staining shows focal, convex bone (arrowheads)—indicative of minimodeling—forming on the smooth
line of the underlying bone matrix (arrows). (B) Fluorescence microscopy image of an ELD-treated specimen. Note continuous, convex calcein labeling at the site of bone minimodelin
(white arrow). Scale bars, 100 μm.smooth line forming the boundary to the underlying bonematrix. Bone
specimens from the ELD-treated OVX monkeys revealed various bone
buds labeled with continuous lines of calcein (Fig. 4B). No monkeys in
the vehicle-treated control group in this study had such focal bone
formation. These ﬁndings in the ELD-treated monkeys are similar to
the histological features of bone minimodeling found in our previous
studies using ELD-administered OVX rats [8,38].
Discussion
We have previously reported that ELD treatment for 6 months
increased lumbar spine BMD, suppressed ovariectomy-induced
increases in bone turnover markers, and improved biomechanical
parameters of lumbar vertebrae in OVX cynomolgus monkeys [6].
Histomorphometrical analysis of bone revealed that both bone forma-
tion and bone resorption parameters in the trabecular bones of the
lumbar vertebrae were suppressed by the ELD treatment. Therefore,-
g
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BMD and improves bone biomechanical properties, at least, in part, by
normalizing bone turnover. In that study, treatment with ELD at doses
of 0.1 μg/kg and 0.3 μg/kg for 6 months increased lumbar spine
(L1–L4) BMD by 7.7% and 10.8%, respectively, compared to the corre-
sponding OVX-vehicle controls, and increased the peak load of intact
L3 vertebra in a compression test by 26.4% and 84.2%, respectively.
Those observations indicated that the ELD treatment improved bone
mechanical properties more than could be explained by the increase
in BMD. Comparing those results with the results from studies of
other anti-osteoporotic agents in the OVXmonkey model, even though
bisphosphonates such as clodronate, ibandronate, and minodronate in-
creased lumbar spine BMD bymore than 10%–30%, they improved peak
load in the compression test by only approximately 30% [39–41].
Bone density fractionation of the vertebral body in the current study
revealed that the ELD treatment slightly shifted bonemineralization to a
higher density. As previously reported, osteoid surface (OS/BS), osteoid
thickness (O.Th), and activation frequency (Ac.f) were reduced in the
lumbar vertebral trabecular bone of the ELD-treated groups compared
with those of the OVX control groups [6]. However, ELD treatment
did not overly affect osteoid maturation time (Omt). These bone
histomorphometrical data indicate that ELD does not accelerate osteoid
mineralization and facilitates secondary mineralization in the vertebral
bone by slowing down bone remodeling. Trabecular connectivity of the
lumbar vertebra was increased by the ELD treatment. Trabecular bones
from ELD-treated groups had higher node-to-node strut length and
lower terminus-to-terminus strut length than did trabecular bones
from the OVX control groups. In general, if BMD is equal, higher connec-
tivity means a stronger bone. Therefore, improvement of trabecular
connectivity in lumbar vertebrae may partly account for the improve-
ment of biomechanical properties in compression.
There are several reports on the effects that various agents for the
treatment of osteoporosis have on the material properties of bone.
Long-term treatmentwith bisphosphonates has been shown to increase
the accumulation of non-enzymatic AGE crosslinks and increase bone
microdamage in canine trabecular bone [22,42,43]. Damaged bone tis-
sue is slowly resorbed by osteoclasts and replaced by new bone tissue
during the bone remodeling process. When bone remodeling is sup-
pressed with agents such as bisphosphonates, the microdamage in the
old bone tissues accumulates due to both a reduction in the removal
of damaged bone tissue and an increase in its formation. There is no
concrete evidence that the levels of microdamage accumulation that
occur in vivo weaken overall bone mechanical properties. We did not
ﬁnd increases in anyparameters of bonemicrodamage in the bone spec-
imens from the ELD-treated groups (Table 2) comparedwith those from
OVX control groups. Rather, 0.3 μg/kg of ELD treatment reduced crack
density and crack surface density of lumbar vertebral bones. Even
though ELD treatment suppressed bone remodeling, it does not seem
to increase the accumulation of bonemicrodamage. This favorable effect
onmicrodamagemay be due to there being no increase in the formation
of AGEs in bone by the treatment with ELD.
Fibrillar type I collagen is the most abundant matrix protein in bone
[3,22,29,30,34,44]. Stabilization of newly formed collagenﬁber is initial-
ly achieved by the formation of covalent crosslinks between neighbor-
ing collagen molecules, and this covalent intermolecular crosslinking
by post-translational modiﬁcation is crucial for the stability of collagen
ﬁbrils. These collagen crosslinks can be divided into two types:
crosslinks controlled by lysyl hydroxylase (LH) and lysyl oxidase
(LOX) (enzymatic crosslinks) and AGE crosslinks (non-enzymatic
crosslinks). Collagen crosslink formation is thought to affect the me-
chanical properties of bone at a material level. Impaired formation of
enzymatic crosslinks and/or an increase in non-enzymatic crosslinks
in bone collagenmay contribute to the impaired bonemechanical prop-
erties seen in aging, osteoporosis, and diabetes mellitus [3,17,19,20,22,
23,28–30]. Active vitamin D, calcitriol, has been shown to strongly
upregulate gene expression of lysyl hydroxylases (LH1 and LH2b) andlysyl oxidase (LOXL2) in osteoblasts in vitro [45]. Treatment with the
active vitamin D3 analog alfacalcidol stimulates LOX expression, and
dose-dependently increases total enzymatic collagen crosslink content
(DHLNL, HLNL, LNL, Pyr, Dpyr) in tibial cortical bones of OVX rats
in vivo [46]. We also demonstrated in a fracture repair OVX rat model
that alfacalcidol stimulated the formation of enzymatic crosslinks in cal-
lus collagen, resulting in an increase of bone strength [22]. In the current
study, ELD treatment increased the total contents of enzymatic collagen
crosslinks (DHLNL, HLNL, LNL, Pyr, Dpyr) in the lumbar vertebral bones
of cynomolgus monkeys, regardless of their bone mineralization status.
This observation suggests that, similar to calcitriol, ELD increases the
production of both immature divalent and mature trivalent enzymatic
crosslinks by directly stimulating LH or LOX gene expression in bones.
Therefore, ELD may be able to improve collagen crosslinks in bones in-
dependently from bone turnover. We have reported that, in the OVX
monkeymodel, elevated enzymatic crosslink formation after treatment
with teriparatide is an independent factor contributing to increasing
vertebral bone strength [16]. Therefore, the increase in the content of
enzymatic crosslinks by ELD treatment in the OVX primate model
(Fig. 3 and Table 3) may contribute to increased bone strength [6]. The
accumulation of young, newly formed collagenmatrix byminimodeling
may account for the observation that accumulation of senescent types of
crosslinking AGEs in bone after treatment with ELD is less than that in
bone from the OVX-vehicle control group.
Histological analysis of trabecular bone sections from ELD-treated
cynomolgus monkeys showed bone minimodeling, which is charac-
terized by focal bone apposition directly to quiescent surfaces with-
out prior bone resorption, as reported previously in OVX rats [8]. At
sites of minimodeling, the mineralization process seems intact
(Fig. 4).Wedo not knowhow this focal bone formation starts. However,
small-size bone formation may affect the bone microarchitecture,
and may ultimately change the degree of mineralization of trabecular
bone.
One of the limitations in this study is the substantial differences that
exist in the biological parameters between the two OVX-control groups
due to the biological variability of nonhuman primates. For each exper-
iment, we selected animals from the colonieswith the same criteria, and
randomly assigned to either OVX-control group or ELD-treated group.
Thus, it is suitable to compare the results from the OVX-control group
with those from the ELD-treated group within the experiment. Howev-
er, it may be difﬁcult to discuss the dose-dependent effects of ELD from
this study.We believe this variability does not confound the interpreta-
tion of the data. Other limitations are the absence of sham-operated
control groups and the relatively short period of treatment. Not all of
themeasurementswere performed on the same bone: Bonemechanical
properties, bonemineralization, and collagen crosslinks were evaluated
in L3 vertebrae; bone microdamage and bone microarchitecture were
measured in L4 vertebrae; and assessment of bone histology was
conducted with L2 vertebrae. Therefore, the improvement of bone me-
chanical properties seen in this study might not directly connect with
the results from other analyses. Nevertheless, we can conclude that
the increase in the degree of bone mineralization and the contents of
enzymatic collagen crosslinks may partly contribute to the increased
bone strength of the lumbar vertebral bone in OVX cynomolgus mon-
keys treated with ELD. We conclude that ELD provides positive effects
on bone quality, complementing our earlier studies showing its positive
effects on bone mass and strength.Acknowledgments
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